Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration
复制标题
每四个月一次和每季度一次服用 Faricimab 与 Ranibizumab 在新生血管性年龄相关性黄斑变性中的疗效
作者：
A. Khanani;Sunil S. Patel;P. Ferrone;A. Osborne;J. Sahni;S. Grzeschik;K. Basu;J. Ehrlich;Z. Haskova;P. Dugel
这项随机临床试验评估了在新生血管性年龄相关性黄斑变性（nAMD）患者中延长faricimab给药的情况。
This randomized clinical trial evaluates extended dosing with faricimab in patients with neovascular age-related macular degeneration (nAMD).